BCRX Q4 2024 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$132M+40.8% YoY

Gross Profit

$125M95.3% margin

Operating Income

-$5M-3.4% margin

Net Income

-$27M-20.4% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+12.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$490M

Total Liabilities

$966M

Stockholders' Equity

-$476M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132M	$93M	+40.8%
Gross Profit	$125M	$92M	+36.7%
Operating Income	-$5M	-$43M	+89.4%
Net Income	-$27M	-$62M	+56.6%

Revenue Segments

Product

$237M100%